SironRX Therapeutics, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 4
Founded: Cleveland OH United States (2010)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2010
NCT00430092
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Sirion Therapeutics, Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

difluprednate (durezol) (3 trials)

prednisone (meticorten) (1 trial)

Drugs in Phase 1 Trials (1)

jvrs-100 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 4)

Corneal Edema (Phase 4)

Edema (Phase 4)

Inflammation (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 3